IR@PKUHSC  > 北京大学临床肿瘤学院  > 介入治疗科
学科主题临床医学
Low-dose, short-interval target vessel regional chemotherapy through the hepatic artery combined with transarterial embolization in gastric cancer patients with liver metastases after failure of first-line or second-line chemotherapy: a preliminary analysis
Chen, Hui; Liu, Peng; Xu, Hai-Feng; Wang, Xiao-Dong; Zhu, Xu; Gao, Song; Cao, Guang; Zhu, Lin-Zhong; Guo, Jian-Hai
关键词gastric cancer hepatic artery hepatic metastasis target vessel regional chemotherapy transarterial embolization
刊名ANTI-CANCER DRUGS
2014
DOI10.1097/CAD.0000000000000027
25期:1页:92-100
收录类别SCI
文章类型Article
WOS标题词Science & Technology
类目[WOS]Oncology ; Pharmacology & Pharmacy
研究领域[WOS]Oncology ; Pharmacology & Pharmacy
关键词[WOS]RANDOMIZED PHASE-II ; COLORECTAL-CANCER ; EUROPEAN-ORGANIZATION ; SURGICAL RESECTION ; COOPERATIVE GROUP ; FOLINIC ACID ; MITOMYCIN-C ; CISPLATIN ; FLUOROURACIL ; OXALIPLATIN
英文摘要

The objective of this study is to evaluate the efficacy and safety of combining low-dose, short-interval target vessel regional chemotherapy delivered through the hepatic artery (TVRCLDSI) with transarterial embolization (TAE) in advanced gastric cancer (AGC) patients with liver metastases after failure of first-line or second-line chemotherapy. All AGC patients with hepatic metastases had an indwelling arterial catheter placed in the hepatic artery and hepatic metastases were embolized with ultrafluid lipiodol, followed by two to three TVRCLDSI treatments in one cycle. After 3 weeks, the efficacy of TVRCLDSI treatment was evaluated using computed tomography (CT) or MRI scans before starting the next cycle. Follow-up assessments were performed every 2 months. The patients received a median of 7 (2-33) TVRCLDSI treatments together with TAE. All 22 AGC patients received a total of 191 TVRCLDSI treatments, which included 80.1% FOLFOX, 11.0% FOLFIRI, and 8.9% DC treatments. The median time-to-progression was 5.97 months; the median survival time was 11.6 months; and the 1-year and 2-year survival rates were 45.5 and 9.1%, respectively. The median overall survival from the diagnosis of liver metastasis (mOS(LM)) was 19.3 months. The most common side effects were grade I-II of abdominal pain, nausea, and vomiting. Combining TAE and TVRCLDSI administration through the hepatic artery for AGC patients with liver metastases resulted in decreased overall dose of chemotherapy, alleviation of side effects, and increased QOL of patient. This approach can be used as salvage therapy for AGC patients with predominant liver metastases after failure of intravenous chemotherapy. (C) 2013 Wolters Kluwer Health vertical bar Lippincott Williams & Wilkins.

语种英语
WOS记录号WOS:000327786900011
资助机构Sanofi-Aventis Company
引用统计
被引频次:3[WOS]   [WOS记录]     [WOS相关记录]
文献类型期刊论文
条目标识符http://ir.bjmu.edu.cn/handle/400002259/58847
专题北京大学临床肿瘤学院_介入治疗科
作者单位Peking Univ, Canc Hosp, Dept Intervent Therapy, Key Lab Carcinogenesis & Translat Res,Minist Educ, Beijing 100142, Peoples R China
推荐引用方式
GB/T 7714
Chen, Hui,Liu, Peng,Xu, Hai-Feng,et al. Low-dose, short-interval target vessel regional chemotherapy through the hepatic artery combined with transarterial embolization in gastric cancer patients with liver metastases after failure of first-line or second-line chemotherapy: a preliminary analysis[J]. ANTI-CANCER DRUGS,2014,25(1):92-100.
APA Chen, Hui.,Liu, Peng.,Xu, Hai-Feng.,Wang, Xiao-Dong.,Zhu, Xu.,...&Guo, Jian-Hai.(2014).Low-dose, short-interval target vessel regional chemotherapy through the hepatic artery combined with transarterial embolization in gastric cancer patients with liver metastases after failure of first-line or second-line chemotherapy: a preliminary analysis.ANTI-CANCER DRUGS,25(1),92-100.
MLA Chen, Hui,et al."Low-dose, short-interval target vessel regional chemotherapy through the hepatic artery combined with transarterial embolization in gastric cancer patients with liver metastases after failure of first-line or second-line chemotherapy: a preliminary analysis".ANTI-CANCER DRUGS 25.1(2014):92-100.
条目包含的文件
条目无相关文件。
个性服务
推荐该条目
保存到收藏夹
查看访问统计
导出为Endnote文件
谷歌学术
谷歌学术中相似的文章
[Chen, Hui]的文章
[Liu, Peng]的文章
[Xu, Hai-Feng]的文章
百度学术
百度学术中相似的文章
[Chen, Hui]的文章
[Liu, Peng]的文章
[Xu, Hai-Feng]的文章
必应学术
必应学术中相似的文章
[Chen, Hui]的文章
[Liu, Peng]的文章
[Xu, Hai-Feng]的文章
相关权益政策
暂无数据
收藏/分享
所有评论 (0)
暂无评论
 

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。